相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis
Merrill D. Benson et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2019)
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
Arnt Kristen et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2019)
TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis
Hannah Rosenblum et al.
CIRCULATION-HEART FAILURE (2018)
Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
Hartmut H. Schmidt et al.
MUSCLE & NERVE (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial
Marcia Waddington-Cruz et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis
Mark Miller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Rajiv Mundayat et al.
NEUROLOGY AND THERAPY (2018)
Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel
Guglielmo Verona et al.
SCIENTIFIC REPORTS (2017)
Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial
Denis Keohane et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years
Fabio A. Barroso et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Cardiac amyloidosis : An update on diagnosis and treatment
Joseph P. Donnelly et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2017)
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy
Merrill D. Benson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects
Lixia Qiang et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy
Natalie J. Galant et al.
CLINICAL SCIENCE (2017)
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
Elizabeth J. Ackermann et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin
Jeffrey N. Higaki et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis
Laura Obici et al.
CURRENT OPINION IN NEUROLOGY (2016)
Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy
Isabel Conceicao et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2016)
Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
Hartmut H-J. Schmidt et al.
MUSCLE & NERVE (2016)
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells
Christoph J. Niemietz et al.
PLOS ONE (2016)
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
Ricardo Sant'Anna et al.
NATURE COMMUNICATIONS (2016)
Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses
Natalie J. Galant et al.
SCIENTIFIC REPORTS (2016)
Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era
M. K. Davis et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases
Joao Melo Beirao et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)
Evolving landscape in the management of transthyretin amyloidosis
Philip N. Hawkins et al.
ANNALS OF MEDICINE (2015)
CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci
Yanshuang Mu et al.
FEBS LETTERS (2015)
Rapid progression of familial amyloidotic polyneuropathy A multinational natural history study
David Adams et al.
NEUROLOGY (2015)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Duncan B. Richards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Bo-Goran Ericzon et al.
TRANSPLANTATION (2015)
CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings
Luis F. Maia et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations
Dorota M. Rowczenio et al.
HUMAN MUTATION (2014)
THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
Teresa Coelho et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Sravan C. Penchala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
Laura Obici et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2012)
Tafamidis
Gerard Said et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Rate of Progression of Transthyretin Amyloidosis
Merrill D. Benson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models
Isabel Cardoso et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Trapping of palindromic ligands within native transthyretin prevents amyloid formation
Simon E. Kolstoe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation
D Adams et al.
BRAIN (2000)
分享论文
